Nolvadex 20 (Tamoxifen Citrate) is supplied as a reference compound commonly examined in research exploring estrogen receptor modulation and related molecular pathways. Each tablet contains 20 mg of the active compound and is produced under controlled laboratory standards to ensure consistency and identity verification.

Research Overview

Nolvadex 20 is categorized as a selective estrogen receptor modulator (SERM). In research settings, it is evaluated for its ability to interact with estrogen receptor sites, offering comparative data in studies of receptor binding, endocrine regulation, and cellular signaling.

Key Research Points

• Commonly referenced in estrogen receptor binding and cell response studies
• Supports comparative assays of blockers vs inhibitors
• Used in evaluation of post-cycle endocrine recovery mechanisms under controlled conditions
• Referenced for data modeling of SERM behavior in laboratory contexts

Reference Sampling & Handling

• Tablet strength: 20 mg Tamoxifen Citrate
• Form: Oral solid, film-coated tablet
• Typical research reference: 10–40 mg equivalent per assay (depending on study parameters)
• Handling: Store in a cool, dry place at 20–25 °C

Reference Sampling Table

All references above represent in-vitro or assay-based sampling equivalents, not therapeutic or medical dosage guidance.

What’s in the Box

• 28 × 20 mg Nolvadex (Tamoxifen Citrate) tablets

Why Choose EU Pharmaceuticals?

EU Pharmaceuticals supplies accurately labeled reference compounds with validated purity and consistency, supporting reproducible laboratory outcomes in pharmacological and biochemical research environments.

For laboratory, educational, and research use only. Not for human or veterinary consumption, ingestion, or therapeutic application. No medical or physiological claims are made or implied. Buyer assumes all responsibility for lawful handling and compliance with applicable regulations.